On medicine, with Dr. Eric Topol
Episode
30 min
Read time
2 min
Topics
Productivity, Health & Wellness, Sales & Revenue
AI-Generated Summary
Key Takeaways
- ✓Pharmacogenomics Gap: Over 150 FDA-approved drugs carry genomic labels that could guide safer dosing or prevent fatal reactions, yet most physicians never order genetic testing before prescribing. The barrier is logistical: tests take up to two weeks and are rarely covered by insurance, making genomic-informed prescribing impractical in standard clinical workflows.
- ✓Stevens-Johnson Syndrome Risk: One in four patients who develop Stevens-Johnson syndrome — a potentially fatal toxic skin reaction — can die from it. The anticonvulsant carbamazepine (Tegretol) is a known trigger, and several countries legally require genomic screening before prescribing it. The US does not, leaving patients exposed to a preventable, life-threatening risk.
- ✓Aspirin Reassessment: Current evidence indicates that adults over 70 without established cardiovascular disease — no prior stent, bypass, or heart attack — face a bleeding risk that outweighs any cardiac benefit from low-dose aspirin. Patients in this demographic should consult their physician about discontinuing routine aspirin use rather than continuing based on outdated guidance.
- ✓Longevity Credibility Test: Topol identifies a practical filter for evaluating longevity experts: anyone actively selling supplements, peptides, or protein products has a financial conflict that undermines their scientific credibility. He estimates the number of researchers genuinely working on healthspan extension without commercial product sales fits on one hand.
- ✓Multimodal AI for Prevention: Lifestyle factors — sleep, diet, exercise, social connection, time in nature — now have substantially stronger randomized trial backing than a decade ago. Topol argues these remain insufficient alone, and that combining proteomic biomarkers, genetic data, environmental exposures, and multimodal AI represents the next layer for predicting and preventing cancer, heart disease, and Alzheimer's.
What It Covers
Cardiologist Eric Topol joins Drug Story host Thomas Getz to examine why pharmacogenomics has failed to reach clinical practice 20 years after the Human Genome Project, how the Vioxx scandal exposed pharmaceutical accountability gaps, and what evidence-based longevity science actually supports versus what supplement sellers promote.
Key Questions Answered
- •Pharmacogenomics Gap: Over 150 FDA-approved drugs carry genomic labels that could guide safer dosing or prevent fatal reactions, yet most physicians never order genetic testing before prescribing. The barrier is logistical: tests take up to two weeks and are rarely covered by insurance, making genomic-informed prescribing impractical in standard clinical workflows.
- •Stevens-Johnson Syndrome Risk: One in four patients who develop Stevens-Johnson syndrome — a potentially fatal toxic skin reaction — can die from it. The anticonvulsant carbamazepine (Tegretol) is a known trigger, and several countries legally require genomic screening before prescribing it. The US does not, leaving patients exposed to a preventable, life-threatening risk.
- •Aspirin Reassessment: Current evidence indicates that adults over 70 without established cardiovascular disease — no prior stent, bypass, or heart attack — face a bleeding risk that outweighs any cardiac benefit from low-dose aspirin. Patients in this demographic should consult their physician about discontinuing routine aspirin use rather than continuing based on outdated guidance.
- •Longevity Credibility Test: Topol identifies a practical filter for evaluating longevity experts: anyone actively selling supplements, peptides, or protein products has a financial conflict that undermines their scientific credibility. He estimates the number of researchers genuinely working on healthspan extension without commercial product sales fits on one hand.
- •Multimodal AI for Prevention: Lifestyle factors — sleep, diet, exercise, social connection, time in nature — now have substantially stronger randomized trial backing than a decade ago. Topol argues these remain insufficient alone, and that combining proteomic biomarkers, genetic data, environmental exposures, and multimodal AI represents the next layer for predicting and preventing cancer, heart disease, and Alzheimer's.
Notable Moment
Topol revealed that Merck pressured the editor of JAMA to suppress his 2001 paper linking Vioxx to elevated heart attack risk — threatening a lawsuit that never materialized. Three years passed before Merck withdrew the drug, despite internal emails showing executives were already aware of the cardiac danger.
Episode Transcript
Hello, and welcome to drug story. I'm Thomas Getz. We'll get back to big shows about specific drugs next week. But this week, we're doing a special episode, a conversation with doctor Eric Topol, the expert cardiologist and researcher. Doctor Topol is the founder and director of the Scripps Research Translational Institute in San Diego. He's the author of the new book SuperAgers. It's a deep dive into the science of aging and longevity with an emphasis on science. I first met Eric about twenty years ago, just after the human genome project had successfully mapped 3,000,000,000 base pairs of DNA. The project seemed like the start of something big. With a deeper understanding of our genetic code, there was so much excitement about personalized medicine. The idea that medicine will be able to treat people based on their specific genetic patterns, allowing earlier and more effective treatment. This was a huge deal, and part of the buzz was that individual drugs would be matched to individual people. Drugs would be more effective and more tolerated because of our DNA. This is called pharmacogenomics, and it was supposed to transform medicine and human health. Well, you may have already guessed where I'm going with this. Here it is twenty years later, and a lot of that excitement has fizzled. Sure. Science has figured out genetic connections on many, many drugs, more than a 100 of them. But a lot of those insights are still sitting on the shelf. Very few doctors are actually tailoring their treatments to individual patient DNA in their clinics. I wanted to talk to doctor Topol about this appointment, about his career, and how he has always put the science first. He shares the story of Vioxx, a pain reliever that he was early to see carried massive risks for people taking it. Eric put his career on the line to help the world know about those those risks. When we talk about longevity and public health and tuberculosis and books and vaccines, it's a really fun and enlightening conversation. I really think that if you're enjoying drug story so far, you'll love this episode. We'll be back next week with another regular episode. Okay. Here's my conversation with doctor Eric Topol. Doctor Topol, if you can explain what pharmacogenomics is and try to capture that moment that we were in about twenty years ago on on the heels of the Human Genome Project. Yeah. Well, first, Thomas, call me Eric so I don't feel so old. Right? Now, back then when we were just getting going with this early consumer genomics. Right, '23 and me and Navagenyx were a couple of the first out, we didn't realize how much more we needed to learn. So we were thinking we could predict the risk of people with various common diseases, you know, whether it's different cancers or, heart disease or type two diabetes. But as it turned out, we only had a very, limited cut of …
Get the full transcript (4,853 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 27-minute episode.
Get Drug Story summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Products
“The anticonvulsant carbamazepine (Tegretol) is a known trigger, and several countries legally require genomic screening before prescribing it.”
other
“why pharmacogenomics has failed to reach clinical practice 20 years after the Human Genome Project”
More from Drug Story
We summarize every new episode. Want them in your inbox?
Similar Episodes
Related episodes from other podcasts
The Daily (NYT)
Mar 29
Our Enduring Fascination With the Kennedys
The Prof G Pod
Aug 13
Why We’re Having Less Sex — and Why It Matters (ft. Dr. Debra Soh)
Modern Wisdom
Jul 20
14 Patterns Behind the World’s Greatest Minds - David Senra - #1126
The Diary of a CEO
Jul 16
Leading Cancer Researcher: They’re Ignoring My Research, Cancer Patients Must Know This!
Modern Wisdom
Jul 13
Why Everyone Is Drowning In Debt (and how to get out) - Caleb Hammer - #1123
Explore Related Topics
This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Drug Story.
Every Monday, we deliver AI summaries of the latest episodes from Drug Story and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime